Prelude announces partnership with AbCellera for oncology ADCs
Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will